<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00560781</url>
  </required_header>
  <id_info>
    <org_study_id>VA IRB# 01023</org_study_id>
    <nct_id>NCT00560781</nct_id>
  </id_info>
  <brief_title>Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs</brief_title>
  <official_title>Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durham VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Durham VA Medical Center</source>
  <brief_summary>
    <textblock>
      This study will test the therapeutic potential of augmenting a stable SSRI regimen with the&#xD;
      neurosteroid pregnenolone to reduce cognitive symptoms and PTSD symptoms in patients&#xD;
      diagnosed with PTSD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See brief summary&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CAPS, BAC-A</measure>
    <time_frame>Prospective</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCL, CD-RISC, CGI, BDI-II</measure>
    <time_frame>Prospective</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Stress Disorders, Post-Traumatic</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pregnenolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregnenolone or Placebo</intervention_name>
    <description>Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-65 years of age, any ethnic group, either sex&#xD;
&#xD;
          2. DSM-IV diagnosis of PTSD by MINI (see schedule of events)&#xD;
&#xD;
          3. No change in SSRI medications for &gt; 4 weeks.&#xD;
&#xD;
          4. No anticipated need to alter any psychotropic medications for the 10-week duration of&#xD;
             the study.&#xD;
&#xD;
          5. Ability to fully participate in the informed consent process, or have a legal guardian&#xD;
             able to participate in the informed consent process.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unstable medical or neurological illness, including seizures, CVA, prostate or breast&#xD;
             cancer&#xD;
&#xD;
          2. Use of oral contraceptives or other hormonal supplementation such as estrogen.&#xD;
&#xD;
          3. Significant suicidal or homicidal ideation.&#xD;
&#xD;
          4. Concomitant medications for medical conditions will be addressed on a case-by-case&#xD;
             base to determine if exclusionary.&#xD;
&#xD;
          5. Current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic&#xD;
             disorder, or cognitive disorder due to a general medical condition; history of&#xD;
             substance dependence within the last 3 months&#xD;
&#xD;
          6. Female patients who are pregnant or breast-feeding.&#xD;
&#xD;
          7. Known allergy to study medication.&#xD;
&#xD;
          8. Drugs with a narrow therapeutic index (e.g. thioridazine, mesoridazine, ziprasidone,&#xD;
             clozapine, etc.) will be excluded, as suggested by the FDA; patients taking these&#xD;
             agents will not be eligible for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine E Marx, MD MA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Durham VAMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durham VAMC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>November 19, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <last_update_submitted>February 25, 2014</last_update_submitted>
  <last_update_submitted_qc>February 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PTSD</keyword>
  <keyword>Pregnenolone</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

